title: Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group.
abstract: Interferon beta (IFNβ) was the first specific disease-modifying treatment licensed for relapsing-remitting multiple sclerosis, and is still one of the most commonly prescribed treatments. A strong body of evidence supports the effectiveness of IFNβ preparations in reducing the annual relapse rate, magnetic resonance (MRI) disease activity and disease progression. However, the development of binding/neutralizing antibodies (BAbs/NAbs) during treatment negatively affects clinical and MRI outcomes. Therefore, guidelines for the clinical use for the detection of NAbs in MS may result in better treatment of these patients. In October 2012, a panel of Italian neurologists from 17 MS clinics convened in Milan to review and discuss data on NAbs and their clinical relevance in the treatment of MS. In this paper, we report the panel's recommendations for the use of IFNβ Nabs detection in the early identification of IFNβ non-responsiveness and the management of patients on IFNβ treatment in Italy, according to a model of therapeutically appropriate care.
authors.affiliation: Neurologia 2-CRESM, AOU San Luigi, Orbassano, Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Bertolotto
authors.forename: Marco
authors.initials: M
authors.lastname: Capobianco
authors.forename: Maria Pia
authors.initials: MP
authors.lastname: Amato
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Capello
authors.forename: Ruggero
authors.initials: R
authors.lastname: Capra
authors.forename: Diego
authors.initials: D
authors.lastname: Centonze
authors.forename: Maria
authors.initials: M
authors.lastname: Di Ioia
authors.forename: Antonio
authors.initials: A
authors.lastname: Gallo
authors.forename: Luigi
authors.initials: L
authors.lastname: Grimaldi
authors.forename: Luisa
authors.initials: L
authors.lastname: Imberti
authors.forename: Alessandra
authors.initials: A
authors.lastname: Lugaresi
authors.forename: Chiara
authors.initials: C
authors.lastname: Mancinelli
authors.forename: Maria Giovanna
authors.initials: MG
authors.lastname: Marrosu
authors.forename: Lucia
authors.initials: L
authors.lastname: Moiola
authors.forename: Enrico
authors.initials: E
authors.lastname: Montanari
authors.forename: Silvia
authors.initials: S
authors.lastname: Romano
authors.forename: Luigina
authors.initials: L
authors.lastname: Musu
authors.forename: Damiano
authors.initials: D
authors.lastname: Paolicelli
authors.forename: Francesco
authors.initials: F
authors.lastname: Patti
authors.forename: Carlo
authors.initials: C
authors.lastname: Pozzilli
authors.forename: Silvia
authors.initials: S
authors.lastname: Rossi
authors.forename: Marco
authors.initials: M
authors.lastname: Salvetti
authors.forename: Gioachino
authors.initials: G
authors.lastname: Tedeschi
authors.forename: Maria Rosaria
authors.initials: MR
authors.lastname: Tola
authors.forename: Maria
authors.initials: M
authors.lastname: Trojano
authors.forename: Maria
authors.initials: M
authors.lastname: Troiano
authors.forename: Mauro
authors.initials: M
authors.lastname: Zaffaroni
authors.forename: Simona
authors.initials: S
authors.lastname: Malucchi
mesh_terms: D057134:Antibodies, Neutralizing / Q000097:blood*; D042241:Early Diagnosis; D006801:Humans; D007155:Immunologic Factors / Q000276:immunology / Q000627:therapeutic use*; D016899:Interferon-beta / Q000276:immunology* / Q000627:therapeutic use*; D007558:Italy; D008279:Magnetic Resonance Imaging; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics / Q000276:immunology*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000175:diagnosis / Q000188:drug therapy / Q000191:economics / Q000276:immunology; D064547:Myxovirus Resistance Proteins / Q000378:metabolism; D016032:Randomized Controlled Trials as Topic
chemical_list: D057134:Antibodies, Neutralizing; D007155:Immunologic Factors; C579071:MX1 protein, human; D064547:Myxovirus Resistance Proteins; D016899:Interferon-beta